We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Events

05 Jun 2025 - 07 Jun 2025
11 Jun 2025 - 13 Jun 2025

Light-Activated Immunotherapy Combined with Engineered Protein Technology Targets Hard-To-Treat Cancer

By HospiMedica International staff writers
Posted on 20 May 2025

In 2024, it was estimated that 26,890 individuals in the U. More...

S. would be diagnosed with stomach cancer, and 10,880 would succumb to the disease. For many, stomach cancer is diagnosed too late, by which time it has already metastasized throughout the abdomen. Recent advances in chemotherapy and immunotherapy have allowed patients with advanced stomach cancer to live for an average of 10 to 17 months following diagnosis. Now, researchers are working on an innovative light-activated immunotherapy technique that could eventually treat patients with stomach cancer that has spread throughout the abdomen.

The approach, developed by bioengineers at University of Texas at Dallas (Dallas, TX, USA), in collaboration with researchers at UT Southwestern Medical Center (Dallas, TX, USA), leverages specially designed molecules and far-red or near-infrared light to “prime” the immune system, encouraging it to target stubborn cancer cells. These novel engineered proteins, when injected into the patient’s abdomen, are designed to bind to cancer cells. Once this binding occurs, a small fiber-optic light is used to apply near-infrared light, activating the engineered proteins to block cancer cell growth and activate immune cells that destroy the cancer cells. When the proteins are activated by light, they capture oxygen and convert it into reactive molecules capable of killing the cancer cells while simultaneously stimulating the immune system.

The lab-engineered molecules, known as betabodies, specifically target tumor cells, leaving healthy tissues unharmed to minimize side effects. By combining the light-activated method with engineered protein technology, this approach utilizes both techniques to effectively eliminate tumors. While the researchers believe this method could work for a range of tumor types, it has not yet been fully tested in humans. The researchers are optimistic that this enhanced therapy could significantly improve patient outcomes.

“There is a dire need for treatments to help people with advanced stomach cancer live longer,” said Dr. Girgis Obaid, assistant professor of bioengineering in the Erik Jonsson School of Engineering and Computer Science. “If successful, our approach ultimately can help patients with stomach cancer live longer after the cancer has spread.”


Gold Member
12-Channel ECG
CM1200B
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
IV Therapy Cart
Avalo I.V Therapy Cart
New
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Rendered isometric views of the iValve are shown in the A) closed and B) open positions (Photo courtesy of Journal of Biomechanics)

Novel Mechanical Heart Valve Improves Blood Flow and Lowers Risk of Blood Clots

Calcific valvular heart disease, which occurs when one or more of the heart's valves fail to open or close properly due to calcification, is expected to affect around 4.5 million people by 2030, making... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.